However, as immunological mechanisms are currently discussed to be involved in patients stopping TKI therapy after long-term molecular remission, we hypothesize that in patients with CML following immunosuppression fewer patients would remain BCR-ABL negative after discontinuation as long as immunosuppression is continued. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.